Page last updated: 2024-10-15

3,4,5-trihydroxybenzamidoxime

Description

3,4,5-trihydroxybenzamidoxime: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135409350
CHEMBL ID1214553
CHEBI ID185704
CHEBI ID94508
SCHEMBL ID4168968
MeSH IDM0201727

Synonyms (28)

Synonym
n',3,4,5-tetrahydroxybenzimidamide
CHEMBL1214553
95933-74-7
n,3,4,5-tetrahydroxybenzamidine
3,4,5-trihydroxybenzamidoxamic acid
trimidox
benzenecarboximidamide, n,3,4,5-tetrahydroxy-
3,4,5-trihydroxybenzamidoxime
ccris 7910
vf 233
vf-233
4-[amino-(hydroxyamino)methylidene]-2,6-dihydroxycyclohexa-2,5-dien-1-one
CHEBI:185704
n',3,4,5-tetrahydroxybenzenecarboximidamide
unii-wrr9sr69te
wrr9sr69te ,
n,3,4,5-tetrahydroxy-benzenecarboximidamide
BRD-K11801786-003-01-7
SCHEMBL4168968
CHEBI:94508
4-[amino(hydroxyamino)methylidene]-2,6-dihydroxycyclohexa-2,5-dien-1-one
DTXSID40914733
cid 5464467
n, 3, 4, 5- tetrahydroxy- benzenecarboximidamide
n,3,4,5-tetrahydroxybenzenecarboximidamide
n,3,4,5-tetrahydroxybenzimidamide
HY-111008
CS-0033949

Compound-Compound Interactions

The study tested the in vitro and in vivo antitumor effects of a drug combination using trimidox (3,4,5-trihydroxybenzamidoxime), a novel inhibitor of ribonucleotide reductase with adriamycin, a widely used anticancer drug.

ExcerptReference
" We examined a new series of RRIs, 3,4-dihydroxybenzohydroxamic acid (Didox) and 3,4,5-trihydroxybenzohydroxamidoxime (Trimidox) for their ability to alter disease progression in murine acquired immunodeficiency syndrome (MAIDS), both alone and in combination with 2',3'-dideoxyinosine (ddI)."( Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).
Birch, NJ; Elford, HL; Gallicchio, VS; Hughes, NK; Mayhew, C; Oakley, O; Phillips, J; Piper, J, 1997
)
" In the present study we tested the in vitro and in vivo antitumor effects of a drug combination using trimidox (3,4,5-trihydroxybenzamidoxime), a novel inhibitor of ribonucleotide reductase with adriamycin, a widely used anticancer drug."( Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia.
Elford, HL; Fritzer-Szekeres, M; Göbl, R; Novotny, L; Rauko, P; Romanova, D; Sedlak, J; Szekeres, T; Vachalkova, A, 1998
)
" We have examined the capacity of two novel RRIs, didox (DI) and trimidox (TRI), in combination with streptozotocin (STZ), to induce hemoglobin and F-cell production."( Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin.
Adunyah, SE; Asakura, T; Elford, HL; Fasold, H; Horiuchi, K; Iyamu, WE; Turner, EA, 2000
)
" In this study, the novel RR inhibitors didox (DX; 3,4-dihydroxybenzohydroxamic acid), and trimidox (TX; 3,4,5-trihydroxybenzamidoxime) were evaluated along with HU for anti-retroviral efficacy in LPBM5-induced retro-viral disease (MAIDS) both as monotherapeutic regimens and in combination with the guanine containing NRTI abacavir (ABC)."( In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.
Duvall, W; Elford, HL; Gallicchio, VS; Hagan, E; Inayat, MS; Mayhew, CN; Sumpter, LR; Yost, EE, 2004
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzenetriolA triol in which three hydroxy groups are substituted onto a benzene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's16 (45.71)18.2507
2000's17 (48.57)29.6817
2010's2 (5.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (97.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]